Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment

Roman Shrestha, Michael Copenhaver, Roman Shrestha, Michael Copenhaver

Abstract

Introduction: Despite unequivocal evidence supporting the use of pre-exposure prophylaxis (PrEP), its scale-up has been gradual overall, and nearly absent among people who use drugs (PWUD). In the present study, we implemented the use of PrEP, as a part of an integrated HIV prevention approach, and explored the experiences and attitudes related to PrEP use among PWUD. Methods: Between September 2016 and July 2017, we recruited 40 HIV-uninfected, methadone-maintained people, who reported HIV-risk behaviors, and were currently taking PrEP. We conducted both quantitative and in-depth semi-structured qualitative interviews that primarily focused on experiences, attitudes, acceptability, disclosure status, risk compensation-related attitudes, and barriers related to PrEP adherence. Results: Results showed that participants were highly satisfied and perceived PrEP as valuable and acceptable for HIV prevention. Participants reported high adherence to PrEP. The most highly endorsed facilitators to PrEP adherence were use of memory aids, no out-of-pocket cost, perceived benefit, and support from social network. The barriers to adherence included side-effects, stigmatization, requirement of daily dosing, and accessibility of PrEP services. Additionally, participants expressed disagreement with the overall risk compensation-related attitudes (i.e., decreased personal concern about engaging in HIV risk behavior due to their perception that PrEP is now fully protecting them from contracting HIV) and indicated no increased engagement in risk behaviors while on PrEP. Conclusions: The results from the current study provide preliminary evidence supporting the successful integration of PrEP within the substance abuse treatment setting, where high risk PWUD are concentrated.

Keywords: HIV prevention; methadone maintenance program; people who use drugs; pre-exposure prophylaxis; substance abuse.

References

    1. Marshall BDL, Friedman SR, Monteiro JFG, Paczkowski M, Tempalski B, Pouget ER, et al. . Prevention And Treatment Produced Large Decreases In HIV Incidence In A Model Of People Who Inject Drugs. Health Affairs (2014) 33:401–9. 10.1377/hlthaff.2013.0824
    1. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. . HIV and risk environment for injecting drug users: the past, present, and future. Lancet (2010) 376:268–84. 10.1016/S0140-6736(10)60743-X
    1. CDC HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2015. Atlanta, GA: (2016).
    1. Bekker L-G, Beyrer C, Quinn TC. Behavioral and biomedical combination strategies for HIV prevention. Cold Spring Harbor Perspect Med. (2012) 2:8. 10.1101/cshperspect.a007435
    1. Brown JL, Sales JM, DiClemente RJ. Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep. (2014) 11:363–75. 10.1007/s11904-014-0228-6
    1. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. (2011) 15:72–9. 10.1007/s10461-011-9894-1
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. (2010) 363:2587–99. 10.1056/NEJMoa1011205
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. (2012) 367:399–410. 10.1056/NEJMoa1108524
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. (2012) 367:423–34. 10.1056/NEJMoa1110711
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. (2012) 367:411–22. 10.1056/NEJMoa1202614
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2013) 381:2083–90. 10.1016/S0140-6736(13)61127-7
    1. CDC Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-−2014: A Clinical Practice Guideline. Washington, DC: Department of Health and Human Services USA—Centers for Disease Control and Prevention; (2014).
    1. Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J, et al. . Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. (2015) 64:1291–5. 10.15585/mmwr.mm6446a4
    1. Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, et al. . Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. (2017) 173:107–16. 10.1016/j.drugalcdep.2016.12.023
    1. Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. (2014) 18:1694–700. 10.1007/s10461-014-0778-z
    1. Kuo I, Olsen H, Patrick R, Phillips G II, Magnus M, Opoku J, et al. . Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. (2016) 164:8–13. 10.1016/j.drugalcdep.2016.02.044
    1. Shrestha R, Karki P, Altice F, Dubov O, Fraenkel L, Huedo-Medina T, et al. . Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. (2017) 22:1228–38. 10.1007/s10461-017-1851-1
    1. Shrestha R, Altice F, Karki P, Copenhaver M. Developing an integrated, brief bio-behavioral HIV prevention intervention for high risk drug users in treatment: the process and outcome of formative research. Front Immunol. (2017) 8:561. 10.3389/fimmu.2017.00561
    1. Liu A, Colfax G, Cohen S, Bacon O. The spectrum of engagement in HIV prevention: proposal for a Pre-Exposure Prophylaxis (PrEP) cascade. In: 7th International Conference on HIV Treatment and Prevention Adherence. Miami (2012).
    1. Shrestha R, Altice F, Karki P, Copenhaver M. Integrated biobehavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. Drug Alcohol Depend. (2018) 10.1007/s10461-018-2099-0 [Epub ahead of print].
    1. Dowling-Guyer S, Johnson ME, Fisher DG, Needle R, Watters J, Andersen M, et al. . Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment (1994) 1:383–92. 10.1177/107319119400100407
    1. Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. (2016) 20:2700–8. 10.1007/s10461-016-1406-x
    1. Tarnowski KJ, Simonian SJ. Assessing treatment acceptance: the abbreviated acceptability rating profile. J Behav Ther Exp Psychiatry (1992) 23:101–6. 10.1016/0005-7916(92)90007-6
    1. Vanable PA, Ostrow DG, McKirnan DJ. Viral load and HIV treatment attitudes as correlates of sexual risk behavior among HIV-positive gay men. J Psychosomat Res. (2003) 54:263–9. 10.1016/S0022-3999(02)00483-X
    1. Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy (2015) 10:1. 10.1186/1747-597X-10-1
    1. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Chaipung B, et al. . Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study. Lancet HIV (2017) 4:e59–66. 10.1016/S2352-3018(16)30207-7
    1. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. (2014) 14:820–9. 10.1016/S1473-3099(14)70847-3
    1. Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba ADM, et al. . Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials. AIDS Behav. (2015) 19:743–51. 10.1007/s10461-014-0859-z
    1. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, De Walque D, et al. . Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS (2011) 25:825. 10.1097/QAD.0b013e32834380c1
    1. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS ONE (2014) 9:e88166. 10.1371/journal.pone.0088166
    1. Mbuagbaw L, van der Kop ML, Lester RT, Thirumurthy H, Pop-Eleches C, Ye C, et al. . Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open (2013) 3:e002954. 10.1136/bmjopen-2013-003950
    1. Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, Sayles JN, et al. . Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 22:256–62. 10.1258/ijsa.2009.009255
    1. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S-J, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care (2011) 23:1136–45. 10.1080/09540121.2011.554528
    1. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. (2010) 54:548–55. 10.1097/QAI.0b013e3181e19a54
    1. Mustanski B, Johnson AK, Garofalo R, Ryan D, Birkett M. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. AIDS Behav. (2013) 17:2173–9. 10.1007/s10461-012-0359-y
    1. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. . What's love got to do with it? explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. (2012) 59:463–8. 10.1097/QAI.0b013e31824a060b
    1. Gilmore HJ, Liu A, Koester KA, Amico KR, McMahan V, Goicochea P, et al. . Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs (2013) 27:560–6. 10.1089/apc.2013.0116
    1. Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Services Res. (2014) 14:231. 10.1186/1472-6963-14-231
    1. Gersh JK, Fiorillo SP, Burghardt L, Nichol AC, Thrun M, Campbell TB. Attitudes and barriers towards pre-exposure prophylaxis (Prep) among high-risk HIV-seronegative men who have sex with men. J AIDS Clin Res. (2014) 10.4172/2155-6113.1000335
    1. Biello KB, Oldenburg CE, Mitty JA, Closson EF, Mayer KH, Safren SA, et al. . The “Safe Sex” conundrum: anticipated stigma from sexual partners as a barrier to PrEP use among substance using MSM engaging in transactional sex. AIDS Behav. (2017) 21:300–6. 10.1007/s10461-016-1466-y
    1. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. (2017) 21:1236–46. 10.1007/s10461-017-1690-0
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. . Pre-exposure prophylaxis to prevent acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2016) 387:53–60. 10.1016/S0140-6736(15)00056-2
    1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. . On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. (2015) 373:2237–46. 10.1056/NEJMoa1506273
    1. Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long acting injectable agents for HIV prevention. Curr Opin HIV AIDS (2016) 11:122–8. 10.1097/COH.0000000000000219

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren